(Q36736647)

16 August 2017

Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis (English)

1 reference

chronic renal insufficiency

16 August 2017

0 references

1 reference

1 reference

Markus Ketteler

1

1 reference

16 August 2017

Marianne Rix

2

1 reference

16 August 2017

Stanley Fan

3

1 reference

16 August 2017

Nicholas Pritchard

4

1 reference

16 August 2017

Ove Oestergaard

5

1 reference

16 August 2017

Scott Chasan-Taber

6

1 reference

16 August 2017

Jeremy Heaton

7

1 reference

16 August 2017

Ajay Duggal

8

1 reference

16 August 2017

Philip A Kalra

9

1 reference

16 August 2017

language of work or name

1 reference

1 May 2008

1 reference

Clinical Journal of the American Society of Nephrology

16 August 2017

1 reference

16 August 2017

3

1 reference

16 August 2017

4

1 reference

16 August 2017

1125-1130

1 reference

Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

The role of metabolic acidosis in the pathogenesis of renal osteodystrophy.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

Oral sodium bicarbonate for the treatment of metabolic acidosis in peritoneal dialysis patients: a randomized placebo-control trial

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

Serum phosphate levels and mortality risk among people with chronic kidney disease

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure

20 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2440270

Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients

20 October 2018

1 reference

12 December 2020

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients

1 reference

12 December 2020

Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study

1 reference

12 December 2020

Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study

1 reference

12 December 2020

Identifiers

DOI

10.2215/CJN.05161107

1 reference

16 August 2017

1 reference

16 August 2017

1 reference